Vizz Opth Sol 1.44% ()
Ocular surface/corneal protection, confirm product mapping ยท Ophthalmology
About Vizz Opth Sol 1.44%
Vizz Opth Sol 1.44% () is a manufactured by Bausch + Lomb (verify), used in the treatment of Ocular surface/corneal protection, confirm product mapping. It received FDA approval in under the pathway.
Note: Fatima list; ex-US detail
Accessing Vizz Opth Sol 1.44% through Reserve Meds
We help patients in the Middle East, India, Africa, and other regions access Vizz Opth Sol 1.44% via established Named Patient Program (NPP) and personal-import pathways. Every order requires a prescription from a licensed physician in the destination country.
What we need from you
- A prescription from a licensed physician in your country of residence.
- A clinical justification from the prescribing physician (why Vizz Opth Sol 1.44% for this patient).
- Destination-country NPP or personal-import paperwork (we help prepare these).
- Patient consent for cross-border drug import under the applicable pathway.
Typical timeline
From request to delivery, most orders for Vizz Opth Sol 1.44% are completed in 2-6 weeks. Timing varies by destination country regulatory review speed and physician documentation turnaround.
Indication context
Vizz Opth Sol 1.44% is indicated for Ocular surface/corneal protection, confirm product mapping. The condition falls within Ophthalmology. For patients with this condition in countries where Vizz Opth Sol 1.44% is not yet registered, NPP access is typically the primary legal pathway for obtaining treatment.
About the manufacturer
Vizz Opth Sol 1.44% is manufactured by Bausch + Lomb (verify). We source drug supply exclusively through DSCSA-compliant US specialty wholesalers, ensuring every unit is authentic, serialized, and chain-of-custody documented.
International regulatory status
- United States: FDA approved ().
- EMA (EU): Status unknown.
- MHRA (UK): Status unknown.
- Other countries: Approval status varies. Reserve Meds coordinates access under each destination country's NPP pathway.
Start a request for Vizz Opth Sol 1.44%
If you or a family member needs Vizz Opth Sol 1.44% and it is not available in your country, submit a request. Our clinical team will review eligibility and reach out as our first cohort opens.
Vizz Opth Sol 1.44%, country access pages
Information on how patients in different countries access Vizz Opth Sol 1.44% through Named Patient Program pathways.
- Vizz Opth Sol 1.44% in United Arab Emirates, The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
- Vizz Opth Sol 1.44% in Saudi Arabia, The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
- Vizz Opth Sol 1.44% in India, India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
- Vizz Opth Sol 1.44% in Kuwait, Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.
- Vizz Opth Sol 1.44% in Qatar, Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
- Vizz Opth Sol 1.44% in Bahrain, Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).
Access by country
Reserve Meds publishes a detailed country deep-dive for Vizz Opth Sol 1.44% in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.